Biosante Pharmaceuticals Inc.  (BPAX) Trade Now »     Rate BPAX  -  Discuss BPAX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BPAX Analysis & Videos »


BPAX: Bull or Bear?

October FDA Calendar Stocks: Tricks or Treats? BPAX

73%

-37.25% in 1342 days Below are six stocks from the BioMedReports.com FDA Calendar with expected catalysts during the month of October, including three pending FDA decisions, updated clinical trial data, and an expected FDA filing to expand the label of an existing product (sNDA). <o:p> </o:p> <o:p>   </o:p> http://www.mikehavrx.com/2009/10/october-fda-calendar-stocks-... <o:p> </o:p> <o:p>   </o:p> <> <> On 8/13/09, BioSante Pharma (NASDAQ: BPAX) announced positive safety data in its ongoing LibiGel Phase 3 clinical development program, reporting that with over 1... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  10/15/09

3 comments

BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential BPAX

73%

+7.37% in 19 days (closed on 10/15/09) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception, and male testosterone deficiency (hypogonadism). The Company’s wholly-owned lead product is LibiGel (transdermal testosterone gel), which is in Phase 3 clinical development by BioSante under dual Special Protocol Assessments (SPAs) for the treatment of female sexual dysfunction (FSD).   <font> http://www.mikehavrx.com/2009/09/biosante-nasdaq-bpax-libigel... </font>   <> <> On 9/22/09, BioSan... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  09/26/09

30 comments

FDA Calendar Extreme Trades: 30 Stocks Under $5 BPAX

73%

+3.83% in 56 days (closed on 09/26/09) <> Below are extreme trades among 30 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 292 entries as of 8/1/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage c... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  08/01/09

16 comments

BioMedReports FDA Calendar: Seven New Extreme Trades BPAX

73%

-24.07% in 45 days (closed on 08/01/09) <> Below are companies with market caps under $250 million from the <font> BioMedReports.com FDA Calendar </font> , which have either pending FDA decisions or pending clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  06/17/09

1 comment

In Search of Healthcare Diamonds in the Rough BPAX

73%

+64.30% in 155 days (closed on 06/17/09) In Search of Healthcare Diamonds in the Rough <> While we are not even halfway through January, the healthcare sector is already active with deal-making, ranging from the rumored $95 buyout of biotech giant Genetech (DNA) by Roche (RHHBY) to Endo's (ENDP) purchase of small-cap, specialty pharma Indevus (IDEV) to Sequenom's (SQNM) $41M offer for emerging diagnostic company EXACT Sciences (EXAS) – which was promptly rebuffed by EXACT's board after the market close on Monday on the promise of a better deal in the works for shareholders. Larger bio-pharma and diagnost... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  01/13/09

Comment

Buyout Binge Begins for Bio-Pharma, Diagnostics BPAX

73%

-6.57% in 3 days (closed on 01/13/09) Buyout Binge Begins for Bio-Pharma, Diagnostics <> <> <> With news late Friday that Roche (RHHBY) is prepared to up its bid for complete control of Genentech (DNA) to $95 from a previous offer of $89 per share and a $41M ($1.50 per share) all-stock takeover offer by Sequenom (SQNM) for EXACT Sciences (EXAS); 2009 is off to a strong start for M&A activity in the bio-pharma and diagnostic space. Larger and well funded bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  01/10/09

4 comments

Virtual Investing at UpDown and MarketGuru BPAX

73%

+42.73% in 8 days (closed on 01/10/09) Virtual Investing at UpDown and MarketGuru <> <> The accompanying table includes the stocks in my MarketGuru virtual portfolio under MikeHavRx , which I began about one week ago. Below is my current UpDown virtual investing portfolio, which is positioned to add some more offensive stock picks such as CME and Apple since it looks like the market rally is gaining momentum. Click on any of the company names below for a link to all of my articles. Start earning real money with zero risk while improving your trading skills and strategies at the <> UpDow... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  01/02/09

2 comments

Is BioSante Next in the Biotech Buyout Binge? BPAX

73%

-41.49% in 48 days (closed on 01/02/09) Is BioSante Next in the Biotech Buyout Binge? <> <> Earlier this week BioSante Pharma (BPAX) reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of LibiGel, which is currently being evaluated for both effectiveness and safety in three Phase 3 clinical trials for the treatment of female sexual dysfunction [FSD]. The Company ended 3Q08 with $17.5M in cash, compared to $22.8M at the end of 2Q08. As illus... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  11/14/08

1 comment

BioSante Back at Key Support Levels BPAX

73%

-0.53% in 12 minutes (closed on 11/14/08) BioSante Back at Key Support Levels <> <> Earlier this week BioSante Pharma (BPAX) reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of LibiGel, which is currently being evaluated for both effectiveness and safety in three Phase 3 clinical trials for the treatment of female sexual dysfunction [FSD]. The Company ended 3Q08 with $17.5M in cash, compared to $22.8M at the end of 2Q08. As illustrated on ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  11/14/08

7 comments

BioSante Back at Key Support Levels BPAX

73%

-0.53% in 2 hours (closed on 11/14/08) BioSante Back at Key Support Levels <> <> Earlier this week BioSante Pharma (BPAX) reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of LibiGel, which is currently being evaluated for both effectiveness and safety in three Phase 3 clinical trials for the treatment of female sexual dysfunction [FSD]. The Company ended 3Q08 with $17.5M in cash, compared to $2.8M at the end of 2Q08. As illustrated on t... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  11/14/08

1 comment

BioSante Pharma Announces Re-Acquisition of Elestrin BPAX

73%

-66.84% in 97 days (closed on 11/14/08) BioSante Pharma (Nasdaq: BPAX) 1-Year Chart Last week, BioSante Pharma (BPAX) announced that it had reacquired Elestrin (estradiol gel) from privately-held Nycomed, which acquired the rights to the product along with its acquisition of Bradley Pharma in February 2008. BioSante will assume all manufacturing, distribution, and marketing responsibilities for Elestrin, which is a fast-drying gel formulation of estradiol (the natural form of estrogen in women) and FDA approved for the treatment of hot flashes in menopausal women. Elestrin will now be added to the <> formal strategic... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  08/09/08

2 comments

BioSante Pharma Explores Its Alternatives for LibiGel BPAX

73%

+6.51% in 13 days (closed on 08/09/08) <> Since I last featured BioSante Pharma (BPAX) on Seeking Alpha in mid-January and my original article in September , the shares have risen by 32.5% and declined by 5.6%, respectively, closing Friday at $5.38 per share within a 52-week range of $2.05 (3/24/08) to $6.29 (8/14/07) and a market cap of $146 million [M]. As of 1Q08 results in early May, the Company has $27.6M in cash, zero debt, 27.2M shares outstanding, and a short interest of 0.7M shares as of mid-July. In addition, a director has purchased 15,000 shares of the stock on the open market at $3.59 per share... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  07/27/08

5 comments

People Bullish on BPAX

fotsirko Analyst N/A over 3 years ago	socialbe Analyst N/A over 3 years ago	Mike Havrilla Principal 73% over 3 years ago
scottbrassel1 Analyst 27% over 4 years ago	Brian Analyst N/A over 4 years ago

People Bearish on BPAX

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.